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Abstract
Background: Human peripheral blood monocytes (Mo) consist of subsets distinguished by expression of
CD16 (FCγRIII) and chemokine receptors. Classical CD16- Mo express CCR2 and migrate in response to
CCL2, while a minor CD16+ Mo subset expresses CD16 and CX3CR1 and migrates into tissues
expressing CX3CL1. CD16+ Mo produce pro-inflammatory cytokines and are expanded in certain
inflammatory conditions including sepsis and HIV infection.
Results: To gain insight into the developmental relationship and functions of CD16+ and CD16- Mo, we
examined transcriptional profiles of these Mo subsets in peripheral blood from healthy individuals. Of
16,328 expressed genes, 2,759 genes were differentially expressed and 228 and 250 were >2-fold
upregulated and downregulated, respectively, in CD16+ compared to CD16- Mo. CD16+ Mo were
distinguished by upregulation of transcripts for dendritic cell (DC) (SIGLEC10, CD43, RARA) and
macrophage (MΦ) (CSF1R/CD115, MafB, CD97, C3aR) markers together with transcripts relevant for
DC-T cell interaction (CXCL16, ICAM-2, LFA-1), cell activation (LTB, TNFRSF8, LST1, IFITM1-3,
HMOX1, SOD-1, WARS, MGLL), and negative regulation of the cell cycle (CDKN1C, MTSS1), whereas
CD16- Mo were distinguished by upregulation of transcripts for myeloid (CD14, MNDA, TREM1, CD1d,
C1qR/CD93) and granulocyte markers (FPR1, GCSFR/CD114, S100A8-9/12). Differential expression of
CSF1R, CSF3R, C1QR1, C3AR1, CD1d, CD43, CXCL16, and CX3CR1 was confirmed by flow cytometry.
Furthermore, increased expression of RARA and KLF2 transcripts in CD16+ Mo coincided with absence
of cell surface cutaneous lymphocyte associated antigen (CLA) expression, indicating potential imprinting
for non-skin homing.
Conclusion:  These results suggest that CD16+ and CD16- Mo originate from a common myeloid
precursor, with CD16+ Mo having a more MΦ – and DC-like transcription program suggesting a more
advanced stage of differentiation. Distinct transcriptional programs, together with their recruitment into
tissues via different mechanisms, also suggest that CD16+ and CD16- Mo give rise to functionally distinct
DC and MΦ in vivo.
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Background
Peripheral blood monocytes (Mo) originate from hemat-
opoietic progenitor cells in bone marrow and play impor-
tant roles in innate and adaptive immunity due to their
ability to differentiate into macrophages (MΦ) and den-
dritic cells (DC) [1-7]. The heterogeneity and plasticity of
MΦ and DC result from their differentiation in specific tis-
sue microenvironments [8-10]. The expression of CD16
(FcγRIII) distinguishes two Mo subsets in peripheral
blood of healthy individuals: a major CD16- subset (80–
95%) and a minor CD16+ subset (5–15%) [11]. Com-
pared to classical CD16- Mo, CD16+ Mo exhibit a more
MΦ-like morphology, produce higher levels of TNF and
IL-1 [12,13], have higher antigen presenting potential
[14-16], and differentiate into DC upon transendothelial
migration in vitro [17]. CD16+ Mo express CX3CR1 and
migrate in response to CX3CL1 [18,19], a membrane-
bound chemokine expressed on inflamed endothelial
cells, while CD16- Mo express CD62L and CCR2 and
migrate in response to CCL2 [18,20], which mediates Mo
migration from bone marrow and recruitment to inflam-
matory sites [2,21]. CD16+ Mo produce IL-6, CCL2, and
matrix metalloproteinase-9 upon interaction with
CX3CL1-expressing endothelial cells [22] and activate
resting T-cells for HIV infection by producing CCR3 and
CCR4 ligands [23]. Together, these findings suggest that
CD16+ and CD16- Mo are recruited into different ana-
tomic sites under constitutive or inflammatory condi-
tions, and play distinct functional roles in immunity and
disease pathogenesis.
A dramatic increase in circulating CD16- Mo has been
reported in inflammatory pathologies such as sepsis, HIV
infection, tuberculosis, and asthma [11,24,25]. Studies of
patients infected with Mycobacterium leprae demonstrated
that CD16+ and CD16- Mo differentiate into DC-SIGN+
MΦ and CD1b+DC-SIGN- DC, respectively, and the pres-
ence of CD1b+DC-SIGN- DC in M. leprae lesions was asso-
ciated with healing [26]. An increased frequency of CD16+
Mo was associated with non-healing Leishmania chagasi
lesions [27]. Thus, CD16+ and CD16- Mo differentiation
into MΦ or DC subpopulations with distinct phenotypes
influences host defenses in infectious disease. Conse-
quently, there is interest in developing therapeutic strate-
gies that target specific Mo subpopulations [6,8,28,29].
Mo heterogeneity is conserved across mammalian species
[7,8,19,30]. In mice, Gr1+CX3CR1low Mo (homolog of
human CD16- Mo) are recruited into the peritoneal cavity
or draining lymph nodes under inflammatory conditions
by mechanisms dependent on CCR2 and CD62L, and
subsequently differentiate into DC [19,31-33]. In con-
trast, Gr1-CX3CR1high (homolog of human CD16+ Mo)
are constitutively recruited into peripheral tissues includ-
ing spleen, gut, lungs, and brain [19]. Gr1-CX3CR1high
patrol vascular endothelium by mechanisms involving
LFA-1 and CX3CR1, and are rapidly recruited into
inflamed tissues where they differentiate into MΦ express-
ing the transcription factors cMaf and MafB and tran-
siently producing TNF-α [33]. Studies in CX3CR1/ApoE
double knockout mice suggest that CX3CR1high Mo play a
critical role in development of atherosclerotic lesions
[34,35]. CX3CR1+ Mo may be precursors for lamina pro-
pria DC, which depend on CX3CR1 to form transepithe-
lial dendrites, enabling direct sampling of luminal
antigens [36]. Furthermore, adoptive transfer studies in
rats demonstrated that CCR2lowCX3CR1high Mo are consti-
tutively recruited into the gut where they give rise to intes-
tinal lymph DC [37]. Studies on the origin of myeloid
pulmonary DC demonstrated that Ly-
6ChighCCR2highCX3CR1low Mo differentiate into CD103+
DC [38,39]), whereas Ly-6ClowCCR2lowCX3CR1high  Mo
give rise to CD11bhigh DC [39,40]. Thus, CX3CR1high and
CX3CR1low  Mo subsets play distinct functional roles
under constitutive and inflammatory conditions.
The developmental relationship between Mo subsets is
poorly understood. In mice, Mo recently emigrating from
bone marrow exhibit a Ly-6Chigh phenotype and gradually
downregulate Ly-6C [41]. Mo acquire CD16 expression
upon exposure to M-CSF [42], TGF-β [17,43], or IL-10
[44], and upregulate CX3CR1 expression upon CCL2
stimulation via CCR2 [45]. Mo differentiation is associ-
ated with decreased CCR2 expression and increased CCL2
production [46]. Engrafted Gr1highCX3CR1low  Mo in
peripheral blood traffic to the bone marrow, differentiate
into Gr1lowCX3CR1high Mo, and contribute to mucosal,
but not splenic, generation of DC [5]. These findings sug-
gest that human CD16+  Mo and mouse Ly-
6ClowCCR2lowCX3CR1high Mo differentiate from CD16-
Mo and Gr1-Ly-6ChighCCR2highCX3CR1low  Mo, respec-
tively.
Here, we investigate the developmental and functional
relationship between CD16+  and CD16-  Mo subsets.
Whole genome transcriptome analysis suggests that these
Mo subsets originate from a common myeloid precursor,
with CD16+ Mo being at a more advanced stage of differ-
entiation and having a more MΦ – and DC-like transcrip-
tion program. Upregulation of the transcription factors
RARA and KLF2 in CD16+ Mo coincided with the absence
of cutaneous lymphocyte associated antigen (CLA)
expression, indicating potential imprinting for non-skin
homing in CD16+ Mo. These results define distinct tran-
scriptional profiles of CD16- and CD16+ Mo subsets sug-
gesting different stages of myeloid differentiation, new
markers to distinguish these Mo subpopulations, and
unique roles in immune responses and inflammatory dis-
eases.BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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Methods
Antibodies
Fluorochrome-conjugated Abs used for FACS analysis
were CD14, CD16, CD19, CD16b, CD66b, CD56, and
CD3 (Beckman Coulter); M-DC8 and CD1c (Miltenyi),
HLA-DR, CD114, C3aR, CD1d and CD43 (BD Pharmin-
gen), CD115 (R&D Systems), CD93/C1qR1 (Chemicon
International), and CXCL16 (R&D Systems). Matched iso-
type controls were from the same source as the Abs.
Flow cytometry analysis
Blood from healthy individuals was collected with
informed consent and IRB approval from Dana-Farber
Cancer Institute. PBMC isolated from peripheral blood by
Ficoll-Paque gradient density centrifugation were stained
with fluorochrome-conjugated Abs and analyzed by
multi-color flow cytometry (BD FACSCalibur or LSRII).
Monocyte sorting
Monocytes (Mo) were isolated by negative selection using
magnetic immunobeads (Monocyte Isolation Kit II,
Miltenyi) as described [18,47]. The purity of sorted Mo
was >98%, as determined by FACS analysis indicating the
expression of CD14 and HLA-DR (monocyte markers)
and absence of CD1c (DC marker), CD56 (NK cell
marker), CD19 (B cell marker), CD3 (T cell marker), and
CD16b and CD66b (neutrophil markers) expression.
CD16+  and CD16-  Mo fractions were further isolated
using CD16 magnetic immunobeads (Miltenyi) with
>85% and >95% purity for CD16+ and CD16- Mo frac-
tions, respectively, as determined by FACS analysis after
staining with CD16 Abs [23]. Mo fractions isolated under
RNase free conditions were stored in Trizol at -80°C for
subsequent RNA extraction.
RNA isolation and microarray analysis
Total RNA from Mo pellets was isolated by Trizol extrac-
tion and purified using RNeasy columns (Qiagen). The
quality of RNA was assessed by visualization of intact
bands corresponding to 18S and 28S rRNA on formalde-
hyde agarose gels. Total RNA (10 μg) from matched
CD16+ and CD16- Mo samples isolated from 4 different
healthy donors was quality tested using an Agilent 2100
Bioanalyzer chip, reverse transcribed, and hybridized on
the GeneChip® Human Genome U133 Plus 2.0 Array
(Affymetrix), which includes 54,000 probe sets on a single
array (i.e., 47,000 transcripts and variants, including
38,500 well-characterized human genes). Primary data
analysis performed using GeneSpring software (Biopoly-
mer core facility, Harvard Medical School) generated Excel
spreadsheets with relative gene expression values for the 4
matched CD16+ and CD16- Mo subsets.
Microarray data analysis
A total of 16,328 probe sets were detected in these 8 sam-
ples (present calls, defined as probe sets detected in at
least 3 samples). Normalization was performed as
described [48] to account for variation between microar-
rays. Missing value estimation was performed using a
modified KNN algorithm [49,50]. T-test was used to iden-
tify probe sets differentially expressed in CD16+  and
CD16- Mo (p < 0.05). These genes were sorted according
to their t-statistics and fold change ratios, which were cal-
culated by computing the mean expression in CD16+ and
CD16-  Mo. Clustering analysis using fuzzy-c-means
[50,51] was performed based on the genes selected by F-
test (n = 2,759 probe sets). False discovery rates (FDR)
[52] were estimated using dChip software (build date: Jan
27 2009) [53] by performing 100 random permutations
using all 8 samples with p-values < 0.05, expression ratio
cut-off = 2.0-fold, and present call cut-off of 20%, yielding
a median FDR of 0.07. Expression ratios for differentially
expressed probe sets were calculated in CD16+  versus
CD16- Mo (cut-off 2-fold; p < 0.05). Heat maps for biolog-
ical function categories were generated by dChip software
using signal values from each of the 8 samples for genes
that were > 2-fold upregulated or downregulated in
CD16+ Mo compared to CD16- Mo. The entire microarray
dataset and technical information requested by Minimum
Information about a Microarray Experiment (MIAME) are
available at the Gene Expression Omnibus (GEO) data-
base under accession number GSE16836 (Transcriptional
profiling of CD16+ and CD16- peripheral blood monocytes from
healthy individuals) http://www.ncbi.nlm.nih.gov/geo.
Gene set enrichment analysis (GSEA)
Gene set enrichment analysis (GSEA) and Molecular Sig-
nature DataBase (MSigDB) http://www.broad.mit.edu
were used to identify differentially expressed gene sets
[54]. GSEA is a computational method that determines
whether an a priori defined set of genes shows statistically
significant concordant differences between two biological
states (e.g. phenotypes). MSigDB contains more than
3000 gene sets for use with GSEA. An enrichment score
(ES) that represents the difference between the observed
and expected rankings from phenotype correlation was
calculated for every gene set. A nominal p-value for the
specific ES was then estimated from an empirical permu-
tation-based null distribution that preserves the complex
correlation structure of the gene expression data. Multiple
testing was corrected via the FDR, with FDR less than 10%
considered statistically significant.
Quantitative Real time RT-PCR
One step SYBR Green real time RT-PCR (Qiagen) was car-
ried out in an iCycler BioRad EN270 PCR machine accord-
ing to manufacturer's recommendations. Absolute
quantification of target gene expression was performedBMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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using a 10-fold serial dilution of purified PCR products as
described [55]. Briefly, 25–50 ng total RNA was reverse
transcribed in 25 μl 1× SYBR Green mix (Qiagen) contain-
ing 0.5 μM primers, and 10 nM fluorescein calibration dye
(Bio-Rad). Agarose gel electrophoresis was used to deter-
mine the size of amplification products (100–200 bp)
and allowed cDNA purification (QIAquick Gel Extraction
Kit; Qiagen) for standard curve preparation (i.e., 200, 20,
2, 0.2, and 0.02 fg cDNA). Primers spanning one or mul-
tiple exons were purchased from Qiagen (i.e., SIGLEC10,
MafB, C1QR, C3AR1, CDKN1C, CSF1R, CSF3R, FcγRIII,
TNFRSF8, ICAM-2 QuantiTect primer sets). Samples with-
out template and reverse transcriptase were used as nega-
tive controls. The concentration of each gene was
normalized to the 28S ribosomal RNA (RRN28S) internal
control [55]. Each RT-PCR reaction was performed in trip-
licate.
Results
Distinct gene expression profiles in CD16+ and CD16- 
monocytes
To define transcriptional profiles of monocyte subsets in
vivo, we performed genome wide transcriptome analysis
of matched CD16+ and CD16- Mo subsets in peripheral
blood of four healthy individuals. We identified 2,759
probe sets that were differentially expressed and 13,569
genes that were similarly expressed in these Mo subsets
(Figure 1A) (GEO database accession number GSE16836,
http://www.ncbi.nlm.nih.gov/geo). Clustering analysis
separated the 8 samples into 2 groups that perfectly
matched CD16+ and CD16- Mo, with 1,402 genes down-
regulated and 1,357 genes upregulated in CD16+ com-
pared to CD16- Mo (Figure 1B). Calculation of expression
ratios for 2,759 differentially expressed probe sets showed
that 250 probe sets were downregulated (corresponding
to 166 genes and 23 unknown transcribed sequences) and
228 probe sets were upregulated (corresponding to 153
genes and 19 unknown transcribed sequences) in CD16+
compared to CD16- Mo (cut-off 2-fold; p < 0.05) (Figure
1C–D, Additional files 1, 2). These 2-fold lists of differen-
tially expressed genes included known markers for CD16+
(i.e., FCGR3A/CD16, CX3CR1, ITGAL/LFA-1, and CD31/
PECAM1) and CD16-  Mo (i.e., CD14, CCR2, SELL/
CD62L, FCGR1/CD64) [18-20] (Additional files 1, 2),
providing initial validation of microarray results. Signa-
ture transcripts for other blood cell lineages were absent in
both CD16+ and CD16- Mo (i.e., CD3 and CD8 for T cells,
CD56 for NK cells, CD19 for B cells, and DC-SIGN and
CD1c for DC), consistent with results obtained by flow
cytometry demonstrating the purity of sorted Mo (>98%)
and absence of DC (i.e., CD1c), NK cell (i.e., CD56), B cell
(i.e., CD19), T cell (i.e., CD3), neutrophil (i.e., CD16b
and CD66b) markers on CD16+ and CD16- Mo. The dif-
ference in relative expression of some probe sets for donor
#1 probably reflects normal donor-to-donor variability,
since post-sort cell viability, RNA quality, and MicroArray
Quality Controls were similar for the four donors. A more
stringent analysis was performed where in addition to a
cut-off >2-fold and p-value < 0.05, probe sets with expres-
sion levels >3-fold higher than background were selected;
by this approach, we identified 132 downregulated and
183 upregulated probe sets in CD16+ compared to CD16-
Mo (data not shown). These genes were further selected
for those with the highest levels of expression (>10,000
AU (arbitrary units), cut-off >2-fold; p-value < 0.05) and
two lists of top genes were generated, with 30 and 31 tran-
scripts upregulated in CD16+ and CD16- Mo, respectively
(Tables 1 and 2). Other genes were differentially expressed
with a difference <2-fold. In CD16+ compared to CD16-
Mo, downregulated markers included the early myeloid
markers CD13 (2,971 ± 1,753 versus 5,656 ± 2,392; ratio
0.53, p-value < 0.05) and CD33 (1,860 ± 703 versus 3,478
± 686; ratio 0.52, p-value < 0.05). Thus, despite a high
level of transcriptional similarity (approximately 83%), a
subset of probe sets were significantly downregulated (n =
250) or upregulated (n = 228) in CD16+ compared to
CD16- Mo, suggesting that these Mo subsets represent dif-
ferent stages of myeloid differentiation and have distinct
biological functions in vivo.
Validation of microarray results and identification of new 
surface markers that distinguish CD16+ and CD16- 
monocytes
Real time RT-PCR was used to quantify expression of nine
differentially expressed genes identified by microarray
analysis. Results in Figure 2 indicate increased mRNA
expression for CD16, C3AR1, ICAM-2, CSF1R, CDKN1C,
TNFRSF8, and LTB, and decreased mRNA expression for
C1QR1 and CSF3R in CD16+ compared to CD16- Mo
(unpaired t-test, p < 0.05, CD16+  versus  CD16-  Mo).
Microarray results were also validated at the protein level
by flow cytometry analysis. Consistent with the microar-
ray and real time RT-PCR results (Figures 1, 2), FACS anal-
ysis demonstrated that CD14lowCD16+  (gate R3)
compared to classical CD14highCD16-  Mo (gate R2)
expressed higher levels of CD115/CSFR1 (M-CSF recep-
tor) and C3AR1, and lower levels of CD114/CSF3R (G-
CSF receptor) and CD93/C1qR1 on the cell surface (Fig-
ure 3A–B). A third Mo subset with an intermediate pheno-
type, CD14highCD16+  Mo, exhibited intermediate
expression levels of CD114 and CD115 and similar levels
of CD93 and C3aR1 compared to CD14lowCD16+ Mo and
CD14highCD16- Mo, respectively (Additional file 3). In
addition, CD16+ compared to CD16- Mo expressed higher
levels of CXCL16 and CD43 and lower levels of CD1d
(Figure 4A–C). As expected, CX3CR1 was also expressed at
higher levels (Figure 4D). Thus, we identified new surface
markers that distinguish CD16- Mo (i.e., CD114, CD93,
and CD1d) and CD16+ Mo (i.e., CD115, C3AR1, CXCL16,
and CD43).BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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Biological functions of differentially expressed genes
Differentially expressed genes, corresponding to 250
downregulated and 228 upregulated probe sets in CD16+
compared to CD16- Mo, were classified into eight func-
tional categories using Gene Ontology. Heat maps for bio-
logical function categories (Figure 5A–H) showed clear
distinctions in patterns of gene expression between the
Mo subpopulations for these categories.
Adhesion molecules, chemokines, and chemokine receptors
Genes upregulated in CD16+  compared to CD16-  Mo
included those coding for the tetraspanins MS4A4A and
MS4A7, adhesion molecules SIGLEC10, ICAM-2, SPN/
CD43, ITGAL/LFA-1/CD11a, CD47, and PCAM1/CD31,
chemokine receptor CX3CR1, and chemokine CXCL16
[56]. Genes downregulated in CD16+ compared to CD16-
Mo included those coding for the tetraspanin MS4A6A,
adhesion molecules ITGAM/CD11b, SELL/L-selectin/
CD62L, CD99, and junctional adhesion molecule like
(JAML or AMICA) [57], and chemokine receptors CCR1,
CCR2, and formyl peptide receptor 1 (FPR1) (Figure 5A).
These results identify SIGLEC10, ICAM-2, SPN/CD43,
CD47, and CXCL16 as new markers upregulated on
CD16+ Mo that are relevant for T cell activation, and FPR1
as a chemokine receptor preferentially expressed on
CD16- Mo. In addition, these results indicate the distinct
trafficking potential of CD16+ and CD16- Mo (i.e., via
CX3CR1 versus CCR2, respectively), consistent with previ-
ous studies [18-20].
Cytokines and cytokine receptors
CD16+ Mo expressed significantly higher levels of mRNA
for the cytokines lymphotoxin beta (LTB) and leukocyte
specific transcript 1 (LST1) and the cytokine receptors TNF
receptor superfamily 8 (TNFRSF8), prostaglandin E recep-
tor 4 (PTGER4), colony stimulating factor 1 receptor
(CSF1R; CSF1, controls Mo/MΦ differentiation and func-
tion), and IL-12RB1. Genes downregulated in CD16+ Mo
Table 1: Top genes upregulated in CD16+ compared to CD16- Mo
CD16+ Mo AU
Gene Symbol CD16+/CD16- Ratio p-value Mean SD GeneTitle
FCGR3A 20,1 0,000 36975 6660 Fc fragment of IgG, low affinity IIIa, receptor for (CD16)
CDKN1C 18,4 0,000 23838 5132 cyclin-dependent kinase inhibitor 1C (p57, Kip2)
MTSS1 5,7 0,000 12285 2678 metastasis suppressor 1
SIGLEC10 4,8 0,000 10657 3068 sialic acid binding Ig-like lectin 10
IFITM1 4,5 0,026 13823 10613 interferon induced transmembrane protein 1 (9–27)
HMOX1 3,5 0,000 16791 4339 heme oxygenase (decycling) 1
TAGLN 3,2 0,000 11950 3480 Transgelin
TCF7L2 3,0 0,000 16772 4608 transcription factor 7-like 2 (T-cell specific, HMG-box)
MS4A7 2,8 0,000 22645 6376 membrane-spanning 4-domains, subfamily A, member 7
CSF1R 2,8 0,000 22838 6537 colony stimulating factor 1 receptor
NAP1L1 2,8 0,000 34370 5546 nucleosome assembly protein 1-like 1
IFITM2 2,5 0,000 58835 17536 interferon induced transmembrane protein 2 (1-8D)
SOD1 2,5 0,000 11300 2491 superoxide dismutase 1
IFITM3 2,5 0,022 40793 15947 interferon induced transmembrane protein 3 (1-8U)
LST1 2,5 0,000 42904 13661 leukocyte specific transcript 1
CX3CR1 2,4 0,041 25882 11806 chemokine (C-X3-C motif) receptor 1
LILRB1 2,4 0,000 15534 4951 leukocyte immunoglobulin-like receptor, subfamily B, member 1
PSCDBP 2,3 0,000 12459 2539 pleckstrin homology, Sec7 and coiled-coil domains, binding protein
ITGAL 2,3 0,000 13269 3384 integrin, alpha L (antigen CD11A)
C6orf187 2,3 0,022 14752 5263 chromosome 6 open reading frame 187
KLF2 2,3 0,000 23783 7614 Kruppel-like factor 2 (lung)
WARS 2,3 0,000 18466 5567 tryptophanyl-tRNA synthetase
MAFB 2,3 0,000 16707 5853 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B
GCH1 2,2 0,022 10956 3586 GTP cyclohydrolase 1 (dopa-responsive dystonia)
CD97 2,2 0,000 10566 3203 CD97 antigen
CTSC 2,2 0,000 10079 2619 cathepsin C
PIK3AP1 2,1 0,000 16825 4941 phosphoinositide-3-kinase adaptor protein 1
MAIL 2,1 0,000 15859 4883 molecule possessing ankyrin repeats induced by lipopolysaccharide
LYN 2,1 0,000 19388 3520 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
BCL2A1 2,1 0,022 11110 5056 BCL2-related protein A1
PECAM1 2,0 0,000 22679 7106 platelet/endothelial cell adhesion molecule (CD31 antigen)
Shown are differentially expressed genes (>2-fold higher in CD16+ compared to CD16- Mo) with the highest expression levels (>10,000 AU). AU, 
arbitrary units.BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
Page 6 of 19
(page number not for citation purposes)
included those coding for the cytokine IL-1RA, platelet-
activating factor receptor (PTAFR), and IL1B and cytokine
receptors IL13RA1, IL27RA (WSX1), colony stimulating
factor 3 receptor (CSF3R; CSF3 controls granulocytes dif-
ferentiation and function), IL6R, and IL6ST/gp130 (a sig-
nal transducer shared by many cytokines, including IL-6
and IL-27) (Figure 5B). These results provide further evi-
dence for pro-inflammatory genes upregulated in CD16+
Mo (e.g., HMOX1 and SOD1) [12] and suggest the ability
of CD16+ and CD16- Mo to respond to distinct cytokines
including IL-12 [58] and IL-13 [59] and IL-6 and IL-27
[60,61], respectively, which has potential implications for
Th1 and Th2 polarization of immune responses. In addi-
tion, these results identify CSF1R and CSF3R as new mark-
ers for CD16+ and CD16- Mo, respectively, with potential
implications for their differentiation fate in vivo.
Immune responses, inflammation, and complement
CD16+ Mo expressed significantly higher levels of mRNA
for the low affinity Fcγ receptor FCGR3A/CD16, IFN-γ-
induced surface molecules IFITM1, IFITM2 and IFITM3,
complement receptor C3AR1, arrestin beta 1 (ARRB1,
which contributes to desensitization of G-protein-cou-
pled receptors), and CD97 (receptor for complement
decay accelerating factor, DAF/CD55). Genes downregu-
lated in CD16+ Mo included those coding for the high
affinity Fcγ receptor FCGR1A/CD64, complement recep-
tor C1QR1, Ca binding proteins S100A12, S100A9, and
S100A8, phospholipase A2, group VII (PLA2G7), Ig super-
family receptor TREM1, neutrophil cytosolic factors NCF1
and NCF4, heparanase (HPSE), chondroitin sulfate prote-
oglycan 2 (versican, CSPG2), amyloid beta (A4) precur-
sor-like protein 2 (APLP2) involved in turnover of MHC
Class I molecules [62], amyloid beta (A4) precursor pro-
tein (APP), and aquaporin AQP9, which plays a role in
Table 2: Top genes upregulated in CD16- compared to CD16+ Mo
CD16- Mo AU
Gene Symbol CD16+/CD16- Ratio p-value Mean SD GeneTitle
S100A12 0,1 0,000 32609 4915 S100 calcium binding protein A12 (calgranulin C)
CSPG2 0,2 0,000 44600 1191 chondroitin sulfate proteoglycan 2 (versican)
CD14 0,2 0,000 29424 2503 CD14 antigen
CD36 0,2 0,000 10283 2743 CD36 antigen (collagen type I receptor, thrombospondin receptor)
CD99 0,2 0,000 11219 925 CD99 antigen
DREV1 0,3 0,000 16902 2260 DORA reverse strand protein 1
CSF3R 0,3 0,000 15383 2884 colony stimulating factor 3 receptor (granulocyte)
FLJ22662 0,3 0,000 24777 3886 hypothetical protein FLJ22662
MS4A6A 0,3 0,000 17295 2171 membrane-spanning 4-domains, subfamily A, member 6A
ITGAM 0,3 0,000 10344 2182 integrin, alpha M (complement component receptor 3)
SELL 0,3 0,038 18878 6604 selectin L (lymphocyte adhesion molecule 1)
CRTAP 0,4 0,000 13026 934 cartilage associated protein
S100A9 0,4 0,000 91116 15677 S100 calcium binding protein A9 (calgranulin B)
GPX1 0,4 0,000 35555 1707 glutathione peroxidase 1
PLP2 0,4 0,000 10014 1672 proteolipid protein 2 (colonic epithelium-enriched)
S100A8 0,4 0,000 114633 17191 S100 calcium binding protein A8 (calgranulin A)
PPBP 0,4 0,025 10279 3787 pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
FPR1 0,4 0,000 23743 4367 formyl peptide receptor 1
EGFL5 0,4 0,000 10378 1126 EGF-like-domain, multiple 5
MNDA 0,4 0,000 26939 7235 myeloid cell nuclear differentiation antigen
KCTD12 0,4 0,000 21488 1640 potassium channel tetramerisation domain containing 12
DKFZp434L142 0,4 0,000 10904 1594 hypothetical protein DKFZp434L142
GRN 0,5 0,000 22341 2163 granulin
LYZ 0,5 0,038 86499 26260 lysozyme (renal amyloidosis)
APLP2 0,5 0,000 23441 2191 amyloid beta (A4) precursor-like protein 2
ALDH2 0,5 0,000 14898 1814 aldehyde dehydrogenase 2 family (mitochondrial)
HIF1A 0,5 0,000 14221 3447 hypoxia-inducible factor 1, alpha subunit
TALDO1 0,5 0,000 21276 2781 transaldolase 1
IRF2BP2 0,5 0,000 21329 4404 interferon regulatory factor 2 binding protein 2
EVI2A 0,5 0,000 10200 1342 ecotropic viral integration site 2A
AMICA 0,5 0,000 10160 945 adhesion molecule AMICA
DPYD 0,5 0,000 10049 1957 dihydropyrimidine dehydrogenase
Shown are differentially expressed genes (>2-fold higher in CD16- compared to CD16+ Mo) with the highest expression levels (>10,000 AU). AU, 
arbitrary units.BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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Genome wide transcriptome analysis identifies new markers for CD16+ and CD16- monocyte (Mo) subsets Figure 1
Genome wide transcriptome analysis identifies new markers for CD16+ and CD16- monocyte (Mo) subsets. (A) 
Total RNA from matched CD16+ and CD16- Mo samples isolated from 4 different healthy donors were reverse transcribed 
and hybridized on GeneChip® Human Genome U133 Plus 2.0 Arrays (Affymetrix). Statistical analyses using one way ANOVA 
was performed to identify differentially expressed genes (p < 0.05). Graph depicts the number of probe sets shared or differen-
tially expressed between CD16+ and CD16- Mo. (B) Graph depicts the fold change expression of probe sets differentially 
expressed in CD16+ versus CD16- Mo. (C-D) Hierarchical clustering analysis based on c-fuzzy means separated the 8 samples 
in 2 groups that perfectly matched CD16+ and CD16- Mo; heat maps were generated using differentially expressed genes (>2-
fold). Red and green signify increased and decreased gene expression, respectively.
Upregulated
Similarly expressed
Downregulated
n=1,357
n=13,569
n=1,402
0
1
10
100
F
o
l
d
 
c
h
a
n
g
e
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
C
D
1
6
+
 
v
s
.
 
C
D
1
6
-
M
o n=1,357
n=1,402
B. Differentially expressed genes A. Present calls
C. Upregulated >2-fold (n=228) D. Downregulated >2-fold (n=250)
CD16- Mo CD16+ Mo
Donors #1   #2   #3   #4 #1   #2   #3   #4
CD16- Mo CD16+ Mo
Donors #1   #2   #3   #4 #1   #2   #3   #4BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
Page 8 of 19
(page number not for citation purposes)
immunological response and bactericidal activity (Figure
5C). These results identify complement-related molecules
C3AR1 and CD97 as new markers for CD16+ Mo, and
C1QR1 as a new marker for CD16- Mo.
Metabolism and stress response
Transcripts upregulated in CD16+  Mo included genes
related to protein synthesis (i.e., tryptophanyl-tRNA syn-
thetase (WARS)), protein catabolism (i.e., cathepsin L
(CTSL), cathepsin C (CTSC)), stress responses (i.e., heme
oxygenase (decycling) 1 (HMOX1), superoxide dismutase
1 (SOD1), heat shock 105 kDa/110 kDa protein 1
(HSPH1), and monoglyceride lipase (MGLL)), and insu-
lin induced gene 1 (INSIG1). Genes downregulated in
CD16+ Mo included those coding for enzymes related to
protein metabolism (i.e., glutaminyl-peptide cyclotrans-
ferase (QPCT), microsomal glutathione S-transferase 1
(MGST1), carboxypeptidase D (CPD), ubiquitin specific
protease 15 (USP15), peptidylprolyl isomerase F (cyclo-
philin F; PPIF), and N-sulfoglucosamine sulfohydrolase
Real-time RT-PCR validation of microarray results Figure 2
Real-time RT-PCR validation of microarray results. The expression of CD16, C3AR1, C1QR1, ICAM-2, CSFR1, 
CSF3R, CDKN1C, TNFRSF8, and LTB mRNA was quantified by SYBR Green real time RT-PCR in CD16+ and CD16- Mo. The 
concentration of each gene was normalized to the 28S rRNA internal control and expressed as fgs RNA of a target gene per 1 
ng rRNA28S. Depicted are results (mean ± SD of triplicate wells; *, p < 0.05, unpaired t-test, CD16+ versus CD16- Mo) 
obtained with matched cells from 2 different healthy donors.
CD16+ Mo CD16- Mo
0
100
200
300
400
500
600
Donor 1 Donor 2
C
1
Q
R
1
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
C1QR1 mRNA
*
*
CSF3R mRNA
0
100
200
300
400
500
Donor 1 Donor 2
C
S
F
3
R
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
*
*
0
3
6
9
12
15
18
21
Donor 1 Donor 2
L
T
B
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
LTB mRNA
*
*
0
200
400
600
800
1000
Donor 1 Donor 2
C
D
1
6
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
 
CD16 mRNA
*
*
ICAM-2 mRNA
0
2
4
6
8
10
12
14
16
Donor 1 Donor 2
I
C
A
M
-
2
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
*
*
0
50
100
150
200
250
300
350
Donor 1 Donor 2
C
D
K
N
1
C
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
) CDKN1C mRNA
*
*
0
20
40
60
80
100
120
Donor 1 Donor 2
C
3
A
R
1
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
C3AR1 mRNA
*
*
CSF1R mRNA
0
100
200
300
400
500
Donor 1 Donor 2
C
S
F
1
R
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
)
*
*
0
4
8
12
16
20
24
28
32
Donor 1 Donor 2
T
N
F
R
S
F
8
/
R
R
N
2
8
S
 
(
f
g
s
/
n
g
) TNFRSF8 mRNA
*
*BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
Page 9 of 19
(page number not for citation purposes)
Differential expression of CD114/CSF3R, CD115/CSF1R, CD93/C1qR1 and C3aR1 on CD16+ and CD16- monocytes Figure 3
Differential expression of CD114/CSF3R, CD115/CSF1R, CD93/C1qR1 and C3aR1 on CD16+ and CD16- mono-
cytes. Freshly isolated PBMC were stained with FITC CD14, PE-Cy5 CD16, and PE CD114, PE CD115, and PE CD93 Abs. 
The expression of CD3aR1 was detected after staining with unconjugated mouse C3AR1 Ab and PE rat anti-mouse Ab (RAM). 
CD14highCD16neg (R2) and CD14lowCD16+ (R3) Mo (A) were analyzed for expression of CD114, CD115, CD93 and C3aR1 
(B). Shown is an overlay histogram from one representative donor of 4 donors examined (B, left panels) and graphs showing 
mean ± SEM for % or MFI of CD114, CD115, CD93 and C3aR1 expression on each Mo subset (B, right panels). (*, Paired t-
test p-value < 0.05, CD16+ versus CD16- Mo; n = 4).
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Differential expression of CD1d, CD43, CXCL16, and CX3CR1 on CD16+ and CD16- monocytes Figure 4
Differential expression of CD1d, CD43, CXCL16, and CX3CR1 on CD16+ and CD16- monocytes. Freshly isolated 
PBMC were stained with Pacific Blue CD3, Alexa700 CD4, FITC CD14, PE-Cy5 CD16, and PE CD1d, PE CD43, PE CXCL16 
or PE CX3CR1 Abs. Gated CD3-CD4lowCD14highCD16- (CD16- Mo) and CD3-CD4lowCD14lowCD16+ (CD16+ Mo) cells were 
analyzed for expression of (A) CD1d, (B) CD43, (C) CXCL16, and (D) CX3CR1. Shown are representative dot plots (left 
panels) and results for 9–13 different donors (right panels). Paired Wilcoxon signed rank test was used to calculated statis-
tical significance (p < 0.05, CD16+ versus CD16- Mo).
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(sulfamidase)/SGSH), stress responses (i.e., aldehyde
dehydrogenase 1 family, member A1 (ALDH1A1), cyto-
chrome P450, family 1, subfamily B, polypeptide 1
(CYP1B1), glutathione peroxidase 1 (GPX1), tumor
necrosis factor, alpha-induced protein 3 (TNFAIP3), and
aldehyde dehydrogenase 2 family (ALDH2)) and other
enzymatic processes (i.e., ribonuclease, RNase A family, 2
(RNASE2) and lysozyme (LYZ)) (Figure 5D). Differential
Biological functions of genes differentially expressed in CD16+ and CD16- monocytes Figure 5
Biological functions of genes differentially expressed in CD16+ and CD16- monocytes. Differentially expressed 
genes were classified based on their biological functions using Gene Ontology as indicated. Heat maps were generated using 
dChip software and include data from matched CD16+ and CD16- Mo from 4 different individuals. In each heat map, upregu-
lated genes are plotted first followed by downregulated genes. Red and green signify increased and decreased gene expression, 
respectively.
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expression of SOD1 and GPX1 in CD16+ and CD16- Mo,
respectively, indicates a distinct antioxidant enzymatic
defense system in these Mo subsets. The upregulation of
WARS expression in CD16+ Mo suggests increased poten-
tial protein synthesis [63], while CTSL and CTSC upregu-
lation may indicate increased potential antigenic
processing and antigen presentation capacity [64].
Signaling and signal transduction
CD16+ Mo expressed significantly higher levels of tran-
scripts for a large number of genes involved in signal
transduction including the protein tyrosine phosphatase
type IVA, member 3 (PTP4A3) and phosphoinositide-3-
kinase, catalytic, gamma polypeptide (PIK3CG, a crucial
signaling molecule required for macrophage accumula-
tion in inflammation [65]). Genes downregulated in
CD16+ Mo included those coding for the interleukin 6 sig-
nal transducer (IL6ST), G protein-coupled receptor 160
(GPR160), jagged 1 (JAG1, the ligand for the receptor
notch 1), protein kinase, cAMP-dependent, regulatory,
type II, beta (PRKAR2B), the CD2 binding protein pro-
line-serine-threonine phosphatase interacting protein 1
(PSTPIP1), and mitogen-activated protein kinase kinase 6
(MAP2K6) (Figure 5E). Thus, CD16+  and CD16-  Mo
exhibit distinct signaling pathway activation, indicating a
distinct activation/differentiation history in vivo.
Cell cycle, proliferation and differentiation
CD16+ Mo were distinguished from CD16- Mo by upregu-
lation of the cell cycle related genes cyclin-dependent
kinase inhibitor 1C (CDKN1C, p27, or KIP2, which is a
negative regulator of cell proliferation [66] induced by
TGF-β [67]), and metastasis suppressor 1 (MTSS1, a tran-
script involved in cytoskeleton organization missing in
metastasis [68]). CD16-  Mo preferentially expressed
mRNA for genes encoding the CD1d antigen (member of
the MHC family that mediates presentation of primarily
lipid/glycolipid antigens to T cells), and myeloid cell
nuclear differentiation antigen (MNDA, which is
expressed in human monocytes and granulocytes and ear-
lier stage cells in the myeloid lineage [69]) (Figure 5F).
These results provide evidence that CD16+ Mo represent a
more advanced stage of differentiation compared to
CD16- Mo.
Cytoskeleton
CD16+ were distinguished from CD16- Mo by expression
of a series of genes related to the cytoskeleton showing
higher expression in CD16+ Mo including CDC42 effector
protein (Rho GTPase binding) 4 (CDC42EP4), microtu-
bule-associated protein 4 (MAP4), and supervillin (SVIL)
and in CD16- Mo including actinin, alpha 1 (ACTN1).
(Figure 5G).
Transcription factors
CD16+ Mo expressed significantly higher levels of mRNA
for several transcriptional factor genes including the mac-
rophage transcription factor v-maf musculoaponeurotic
fibrosarcoma oncogene homolog B (MafB, an essential
determinant of the monocytic program in hematopoietic
cells [7,70,71]), the pleckstrin homology, Sec7, and
coiled-coil protein-binding protein (PSCDBP or CYBR, a
cytohesin-1-binding protein expressed in NK cells stimu-
lated with IL-2 and IL-12 that plays a role in integrin-
mediated cell adhesion [72]), the Kruppel-like factor 2
(KLF2, reported to license mature T-cells for trafficking
from the thymus and recirculation through secondary
lymphoid tissues [73]), and retinoic acid receptor, alpha
(RARA, expressed in dendritic cells [74] and involved in
myeloid differentiation [75] and imprinting for gut hom-
ing [76,77]). In contrast, CD16-  Mo preferentially
expressed the aryl hydrocarbon receptor (AHR, a ligand
dependent E3 ubiquitin ligase [78] and modulator of
anti-viral immunity [79]) transcript (Figure 5H). Both
CD16+ and CD16- Mo lacked PU.1 expression, a transcrip-
tion factor upregulated in DC [71], as demonstrated by
microarray analysis and RT-PCR (data not shown). Thus,
CD16+ and CD16- Mo express distinct transcription fac-
tors that may differentially regulate biological functions in
vivo.
Gene set enrichment analysis (GSEA)
To extract further meaning from differentially expressed
genes in CD16+ and CD16- Mo, GSEA, a knowledge based
approach for interpreting genome-wide expression pro-
files [54], was applied to test for sets of genes that share
common biological functions. Enrichment scores (ES),
nominal p-values, false discovery rate (FDR), and family
wise-error rate (FWER) values were generated for a large
number of gene sets for GSEA available on the Molecular
Signatures Database (MSigDB) of the Broad Institute. One
gene set was significantly enriched in CD16- compared to
CD16+ Mo: HADDAD_HPCLYMPHO_ENRICHED (p <
0.001; both FDR q-value and FWER p-value- < 0.2).
According to MSigDB, this set includes genes enriched in
CD45RAhiLin-CD10+  versus CD45RAintCD7-  and
CD45RAhiCD7hi  hematopoietic progenitor cells [80].
Four uncharacterized open reading frames upregulated in
hematopoietic progenitor cells (i.e., C18ORF1,
CYORF15B, C6ORF62, and C6ORF111) [80] were signif-
icantly enriched in CD16- Mo.
GSEA also identified several gene sets relatively enriched
in CD16+ or CD16- Mo, but with a lower statistical signif-
icance likely related to the limited number of samples (p
< 0.001 and FDR = 1). These analyses showed that CD16+
Mo were enriched in genes related to NK cell mediated
toxicity (i.e., FcγRIIIA, PIK3CG, NFATC1, ITGAL, and
ICAM-2), inositol phosphate metabolism (i.e., PIK3CG),BMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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actin binding (i.e., MTSS1, COTL1, and SVIL), and oxida-
tive stress (i.e., CDKN1C, ETS1, CD47, LYN, and VIL2). In
contrast, CD16- Mo were enriched in genes related to
hematopoietic cell lineage (i.e., CD1d, IL1β, FcγRIA,
ITGAM, CSF3R, CD36, and CD14), receptor mediated
endocytosis (i.e., SORL1, STAB1, FCGR1A, and CD14),
arginine and proline metabolism (i.e., ALDH2, P4HB,
and ALDH1A1), nontypable Haemophilus influenzae
(NTHi) pathway (i.e., IL1B and MAP2K6), and lipid bind-
ing molecules (i.e., CD1D, PTAFR, ALDH1A1, and
PLA2G7). Overall, these results provide new insights into
the developmental relationship between CD16+  and
CD16- Mo, with CD16- Mo being more closely related to
hematopoietic progenitor cells and having higher endocy-
tosis activity, while CD16+ Mo being at a more advanced
stage of Mo differentiation with more effector functions
related to antigen presentation, migration, and cytotoxic-
ity.
Pattern recognition receptor expression in CD16+ and 
CD16- monocytes
Both Mo subsets expressed TLR1, TLR2, TLR4, TLR5, and
TLR8 but not TLR3, TLR6, TLR7, TLR9, and TLR10 mRNA
(data not shown). Considering that CD16+ Mo express
low levels of the LPS co-receptor, CD14 [11], and that TLR
stimulation was previously implicated in myeloid differ-
entiation [26,81], we tested whether genes associated with
TLR pathway were upregulated in these cells. However,
GSEA rejected this hypothesis. Nonetheless, microarray
results demonstrated slight downregulation of TLR2,
TLR4, TLR5, and TLR8, together with slight upregulation
of MyD88, a key adaptor for these TLRs [82], in CD16+
compared to CD16- Mo
Potential imprinting for non-skin homing in CD16+ 
monocytes
We demonstrated increased expression of RARA mRNA in
CD16+ compared to CD16- Mo (Figure 5H and 6A). SLP-
76 (Src-homology 2 domain-containing leukocyte spe-
cific phosphoprotein of 76 kDa), a RA-induced target
[75], was significantly upregulated in CD16+ compared to
CD16- Mo (6363 ± 611 versus 3882 ± 565; CD16+/CD16-
ratio 1.64; p = 0.005), indicative of RARA pathway activa-
tion in CD16+ Mo. Activation of the RARA transcription
factor pathway leads to loss of skin homing potential in
lymphocytes via downregulation of the cutaneous lym-
phocyte-associated antigen (CLA, an epitope on PSGL-1)
[83] and imprinting for mucosal homing [77]. CLA
expression was quantified on CD16+ and CD16- Mo by
FACS on PBMC from healthy individuals. CLA expression
was undetectable on all CD16+ Mo and a fraction of
CD16- Mo (Figure 6B). The frequency of CLA+CD16- Mo
was negatively correlated with the frequency of CD16+ Mo
(Figure 6C). CD16+ Mo express M-DC8 (an epitope on
PSGL-1) [13], which was previously reported to be
expressed by a subset of mucosal DC [84] (Figure 6D).
CX3CR1 expression on CD16+ Mo (Figure 4D) [18] may
contribute to recruitment of these cells into CX3CL1
expressing tissues including the gut. These results indicate
that CD16+ Mo, similar to RA-stimulated T-cells [77], lack
expression of the skin-homing addressin CLA and there-
fore are potentially imprinted for non-skin homing.
Because retinoic acid (RA) is an important factor driving
myeloid differentiation [75], this reprogramming of
CD16+ Mo homing potential may be in part a conse-
quence of RARA pathway activation.
Discussion
In this study, we define transcriptional profiles of human
CD16+  and CD16-  monocytes (Mo) and provide new
insights into their developmental relationship and bio-
logical functions. Despite remarkable transcriptional sim-
ilarity (approximately 83%), a significant number of
transcripts were differentially expressed (n = 2,759), with
228 and 250 >2-fold upregulated and downregulated,
respectively, in CD16+ compared to CD16- Mo. Differen-
tially expressed genes related to cell-to-cell adhesion and
trafficking, immune responses and inflammation, metab-
olism and stress response, signaling and signal transduc-
tion, cell cycle, proliferation, and differentiation,
cytoskeleton, and regulation of transcription. Gene set
enrichment analysis (GSEA) demonstrated that CD16+
Mo are enriched in genes related to NK-mediated cytotox-
icity, inositol phosphate metabolism, actin binding, and
oxidative stress, while CD16- Mo are enriched in genes
related to hematopoietic cell lineage, receptor-mediated
endocytosis, arginine and proline metabolism, NTHi
pathway, and lipid binding. The transcriptional profiles
suggest that CD16+ and CD16- Mo subsets originate from
a common myeloid precursor, with CD16+ Mo being at a
more advanced stage of myeloid differentiation and hav-
ing distinct biological functions in vivo.
Previous studies in mice provide evidence for a develop-
mental relationship between Ly6ChighCCR2highGr1+CX3
CR1low  and Ly6ClowCCR2lowGr1-CX3CR1high  Mo
(homologs of human CD16-  and CD16+  Mo, respec-
tively), with Ly6ClowCCR2lowGr1-CX3CR1high Mo being
more mature and derived from
Ly6ChighCCR2highGr1+CX3CR1low Mo [5,41,85]. Likewise,
studies on human Mo demonstrated the ability of CD16-
CX3CR1low Mo to differentiate into CD16+CX3CR1high
Mo upon stimulation with TGF-β, IL-10, M-CSF, or CCL2
[17,43-45]. Our comparative transcriptome analysis pro-
vides further evidence for the idea that CD16- Mo origi-
nate from a common granulocyte-macrophage (GM)
precursor and give rise to CD16+ Mo, which are more
closely related to macrophages (MΦ) and dendritic cells
(DC). CD16-  Mo preferentially expressed granulocyte-
associated transcripts (i.e., CSF3R, formyl peptide receptorBMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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Differential expression of RARA mRNA and PSGL-1 epitopes CLA and M-DC8 on CD16+ and CD16- monocytes Figure 6
Differential expression of RARA mRNA and PSGL-1 epitopes CLA and M-DC8 on CD16+ and CD16- mono-
cytes. (A) Differential expression of RARA mRNA in CD16+ and CD16- Mo was extracted from microarray data set results 
and expressed as relative fluorescence units. (B-D) Freshly isolated PBMC were stained with Pacific Blue CD3, Alexa700 CD4, 
PE-Cy5 CD16, FITC CLA and PE M-DC8 Abs. Gated CD3-CD4lowCD14highCD16- (CD16- Mo) and CD3-
CD4lowCD14lowCD16+ (CD16+ Mo) cells were analyzed for expression of CLA (C) and M-DC8 (D). (B and D) Shown are 
representative dot plots (left panels) and results for 13 different donors (right panels). Paired Wilcoxon signed rank test 
was used to calculated statistical significance (p < 0.05). (B) Spearman correlation (r and p values) and linear regression (r2 
value) were calculated to examine the relationship between the frequency of CD16-CLA+ Mo and CD16+ Mo.
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1 (FPR1), the calgranulins S100A8, S100A9, and
S100A12), and myeloid markers (i.e., CD14, MNDA,
TREM-1, CD1d, and C1qR1/CD93), together with tran-
scripts suggesting an increased potential for receptor-
mediated endocytosis via molecules such as CD14 and
FCGR1A/CD64 [85,86]. In contrast, CD16+ Mo preferen-
tially expressed MΦ (i.e., CSF1R/CD115, MafB, EGF mod-
ule-containing mucin-like hormone receptor (EMR)1-3,
CD97, and C3aR) [86] and DC markers (i.e., SIGLEC10,
CD43, CXCL16, and RARA) [56,74,87,88]. CD16+ Mo
expressed higher levels of transcripts encoding the
cysteine protease cathepsin L (CTSL), which contributes
to phagocytic-endocytic proteolysis in DC for subsequent
antigen presentation [64]. Upregulation of transcripts
encoding dipeptidyl-peptidase I, CTSC [89] may further
enhance antigen processing by CD16+ Mo or DC derived
from these cells. Although some studies classified CD16+
Mo as DC based on their increased antigen presenting
ability [14-16] and transcriptional profile similarities
[16], a recent compendium analysis of transcriptional
profiles demonstrated that CD16+HLA-DR+ cells are more
closely linked to myeloid CD14+ cells than to DC subsets
in peripheral blood [90]. Our results demonstrate that
CD16+ Mo share approximately 83% of their transcripts
with CD16- Mo, supporting the idea that these two Mo
subsets are developmentally related.
Recruitment of CD16+ and CD16- Mo into tissues is medi-
ated via distinct molecular mechanisms [7,8]. Our gene
expression analysis confirms differential expression of
adhesion molecules and chemokine receptors previously
reported to be preferentially expressed on CD16+ Mo (i.e.,
LFA-1, PECAM/CD31, CX3CR1) and CD16-  Mo (i.e.,
CCR1, CCR2, and L-selectin/CD62L) [18-20]. We also
identified new cell surface markers and other molecules
that are differentially expressed in these Mo subsets and
may influence their trafficking and migration into tissues.
The tetraspanins MS4A4A and MS4A7, adhesion mole-
cules SIGLEC10 and ICAM-2, and membrane-bound
chemokine CXCL16 [56] were preferentially expressed by
CD16+ Mo, whereas the tetraspanin MS4A6A, adhesion
molecules CD99 and junctional adhesion molecule like
(JAML or AMICA) [57], and chemokine receptor FPR1
were preferentially expressed by CD16- Mo. CD31 and
CD99 are involved in distinct steps of Mo transendothe-
lial migration [91,92]. Expression of CXCL16, a chemok-
ine expressed by DC [56], on the surface of CD16+ Mo
may facilitate interaction with CXCR6+ cells (i.e., NKT and
activated CD4+ and CD8+ T-cells [56]) and retention of
CXCR6+  cells in tissues. Similar to mouse and rat
CCR2lowCX3CR1high  Mo [37,41], CD16+  Mo expressed
higher levels of SPN/CD43 (sialophorin, leukosialin,
large sialoglycoprotein or gp115), a ligand for ICAM-1
[93,94], and the macrophage adhesion receptor siaload-
hesin (Siglec-1) [95]. CD43 has both adhesive and anti-
adhesive properties [96], mediates DC maturation [88],
and contributes to regulation of immunological synapse
formation [97]. CD47, a receptor for thrombospondin-1
(TSP-1), is preferentially expressed by CD16+ Mo. CD47
ligation selectively inhibits the development of human
naive T cells into Th1 effectors by decreasing IL-12 and
TNF-α production by Mo-derived DC [98,99]. Consistent
with these findings, CD16- and CD16+ Mo may induce
Th1 and Th2-like differentiation, respectively [100]. How-
ever, CD16+  Mo express IL-12RB1, which favors Th1
polarization [58], whereas CD16- Mo express receptors for
the Th2 cytokines IL-6 and IL-13 [59] and the anti-Th1
cytokine, IL-27 [60,61]. Accordingly, the influence of
CD16+ and CD16- Mo on Th1 versus Th2 polarization of
immune responses is likely to be highly dependent on the
local microenvironment within tissues.
CD16+ Mo expressed high levels of transcripts for RARA,
which controls transcription of genes involved in cell traf-
ficking and mucosal homing. RA imprints lymphocytes
with non-skin mucosal homing properties by decreasing
cutaneous lymphocyte-associated antigen (CLA, an
epitope on PSGL-1) expression [83] and increasing
expression of CCR9 and integrin beta 7, two mucosal
addressins [77]. RA also controls reciprocal differentiation
of Th17 and regulatory T cells [101], modulates myeloid
gene expression and differentiation [75], and regulates
survival and antigen presentation by DC [74]. Consistent
with our hypothesis that the RARA pathway is activated in
CD16+ Mo, we demonstrated CLA downregulation on
these cells, together with upregulation of two RA-induced
targets: SLP-76 [75] and CXCL16 [102]. RA induces
mucosal-type DC, which produce TGF-β and thereby
imprints T-cells for gut homing by inducing CCR9 and
integrin beta 7 [76]. CD16+ Mo-derived MΦ and DC con-
stitutively produce TGF-β [23,100], but whether they also
instruct T-cells for gut homing remains to be determined.
KLF2 mRNA is expressed at very high levels and signifi-
cantly upregulated in CD16+ compared to CD16- Mo.
KLF2 belongs to a family of zinc-finger transcription fac-
tors that is induced by PI3K signaling [103] and controls
expression of several genes including those coding for
CD62L, CCR7, integrin beta7, sphingosine-1-phosphate
receptor (S1PR1) [73], and lymphotoxin beta [104].
CCR7 and CD62L are essential for migration into lymph
nodes, S1P1 regulates T-cell thymic egress and recircula-
tion [105], and integrin beta 7 mediates cell recruitment
into Peyer's patches and mesenteric lymph nodes [106].
Together, these findings raise the possibility that preferen-
tial expression of KLF2 in CD16+  Mo may confer an
increased potential for trafficking.
CD16+ compared to CD16- Mo express very high levels of
transcripts for cyclin-dependent kinase inhibitor 1CBMC Genomics 2009, 10:403 http://www.biomedcentral.com/1471-2164/10/403
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(CDKN1C or p57/KIP2) (18.4-fold increase) and metasta-
sis suppressor 1 MTSS1 (5.7-fold increase). CDKN1C is a
potent inhibitor of several G1 cyclin-dependent kinase
(cdk) complexes, and negative regulator of G1/S cell cycle
transition and cell proliferation [66]. CDKN1C [66] and
MTSS1 [68] are candidate tumor suppressor genes, and
their high expression is consistent with the inability of Mo
to proliferate [7]. CDKN1C is induced by TGF-β [67], a
cytokine known to induce CD16+  Mo differentiation
[17,43]. Thus, our results are consistent with a potential
link between TGF-β pathway activation and CD16+ Mo
differentiation in vivo.
Several transcripts related to cell activation were upregu-
lated in CD16+ Mo including LTB, TNFRSF8, leukocyte
specific transcript 1 (LST1), IFITM1-3, HMOX1, superox-
ide dismutase-1 (SOD-1), tryptophanyl tRNA synthetase
(WARS), and monoglyceride lipase (MGLL), indicating
increased activation of CD16+ compared with CD16- Mo.
LST1 [107], HMOX1 [108], SOD-1, and WARS are
induced by stimulation with lipopolysaccharide [109].
The role of LST1 in immune regulation remains elusive.
HMOX1 modulates Mo inflammatory responsiveness by
decreasing LPS-induced TNF and IL-1β expression [108].
WARS and indoleamine 2,3-dioxygenase (IDO) are
responsible for tryptophan use in protein synthesis and
degradation, respectively [63]. WARS was identified as a
molecular marker for Mo differentiation into MΦ [110]
and DC [111]. These results suggest increased activation
of CD16+ compared to CD16- Mo in vivo.
The CD16+ Mo subset includes two subsets with distinct
levels of CD14 expression: CD14highCD16+  and
CD14lowCD16+ [11,112]. CD14highCD16+ Mo exhibit a
phenotype intermediate between that of
CD14highCD16neg  and CD14lowCD16+  Mo in terms of
adhesion molecule (e.g., CL62L) and chemokine receptor
expression (e.g., CCR2, CXCR2, and CX3CR1) [18]. Both
CD14highCD16+ and CD14lowCD16+ Mo contributed to
the transcriptional profile of CD16+ Mo in this study. The
expression of some genes we identified as markers for
CD16+  Mo may be distinct on CD14highCD16+  and
CD14lowCD16+ Mo. Consistent with this prediction, we
demonstrated intermediate expression of CD115 and
CD114 on CD14highCD16+  Mo compared to
CD14highCD16neg  and CD14lowCD16+  Mo, and high
expression of CD93 and C3aR1, similar to that on
CD14highCD16-  and CD14lowCD16+  Mo, respectively
(Additional file 3). These findings suggest a developmen-
tal relationship between these Mo subsets in which
CD14highCD16neg  Mo, CD14highCD16+  Mo, and
CD14lowCD16+ Mo represent sequential stages of mono-
cyte differentiation [41].
Conclusion
Comparative transcriptome analysis of CD16+ and CD16-
Mo indicates that CD16+ Mo represent a more advanced
stage of myeloid differentiation with a more MΦ – and
DC-like transcription program, whereas CD16- Mo are
more closely related to a common myeloid precursor.
Given the ability of CD16+ and CD16- Mo to be recruited
into specific tissues via  distinct mechanisms, these Mo
subsets are likely to give rise to DC and MΦ subpopula-
tions with distinct phenotypes and roles in immunity and
disease pathogenesis. Further studies to characterize phe-
notypic differences between CD16+  and CD16-  Mo-
derived DC and MΦ are relevant for development of DC-
based vaccines, and will also provide a better understand-
ing of their functional roles in immune responses, inflam-
mation, and disease pathogenesis.
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